A5045760753- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Spondyloarthritis Studies and Treatments
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Systemic Sclerosis and Related Diseases
- Musculoskeletal synovial abnormalities and treatments
- Viral Infections and Immunology Research
- Orthopedic Surgery and Rehabilitation
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Acute Lymphoblastic Leukemia research
- Hepatitis C virus research
- Psoriasis: Treatment and Pathogenesis
- Pregnancy and Medication Impact
- HER2/EGFR in Cancer Research
- Inflammatory Bowel Disease
- Peripheral Neuropathies and Disorders
- Ocular Oncology and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Reproductive System and Pregnancy
- Multiple Sclerosis Research Studies
- Adolescent and Pediatric Healthcare
Erasmus MC
2016-2025
Erasmus University Rotterdam
2013-2025
Center for Rheumatology
2015-2024
Maasstad Ziekenhuis
2016-2022
Haga Hospital
2022
Groene Hart Ziekenhuis
2022
Leiden University Medical Center
2022
St. Vincent's Hospital
2022
Reinier de Graaf Hospital
2022
Arthritis Society
2022
<h3>Objective</h3> To investigate if erythrocyte-methotrexate-polyglutamate (MTX-PG) concentrations in patients with rheumatoid arthritis (RA) are associated disease activity or adverse events. <h3>Methods</h3> We used a longitudinal study design two cohorts. The derivation cohort included 102 and the validation 285 RA on MTX. measured erythrocyte-MTX-PG 1–5 glutamate residues at 3 months, 6 months 9 after MTX start liquid chromatography (LC)-mass spectrometry (MS)/MS assay. Outcomes were...
Objectives The aim of this study is to evaluate the effectiveness two tapering strategies after achieving controlled disease in patients with rheumatoid arthritis (RA), during 1 year follow-up. Methods In multicentre single-blinded (research nurses) randomised trial, RA were included who achieved disease, defined as a Disease Activity Score (DAS) ≤ 2.4 and Swollen Joint Count (SJC) 1, treated both conventional synthetic disease-modifying antirheumatic drugs (csDMARD) TNF inhibitor. Eligible...
Objectives To investigate whether there is a window of opportunity for psoriatic arthritis (PsA) patients and to assess which patient characteristics are associated with longer diagnostic delay. Methods All newly diagnosed, disease-modifying antirheumatic drug-naïve PsA who participated in the Dutch southwest Early cohoRt had ≥3 years follow-up were studied. First, total delay was calculated as time period between symptom onset diagnosis made by rheumatologist then split into physician...
Altered B cell receptor (BCR) signaling has been implicated in the pathogenesis of rheumatoid arthritis (RA). Here we aimed to identify aberrations autoantibody-positive and autoantibody-negative RA patients by performing a comprehensive analysis BCR cascade different subsets. We first optimized phosphoflow cytometry for an in-depth across immunoglobulin isotypes healthy donors. Subsequently, compared circulating subsets from treatment-naïve, newly-diagnosed controls (HCs). observed...
Objective The objective was to predict insufficient response 3 months methotrexate (MTX) in DMARD naïve rheumatoid arthritis patients. Methods A Multivariable logistic regression model of patients starting MTX developed a derivation cohort with 285 clinical multicentre, stratified single-blinded trial, performed seven secondary care clinics and tertiary clinic. validated validation 102 at Outcome (disease activity score (DAS)28 >3.2) after treatment. Clinical characteristics, lifestyle...
Whether deep neural networks can exhibit emergent behaviour is not only relevant for understanding how learning works, it also pivotal estimating potential security risks of increasingly capable artificial intelligence systems. Here, we show that training gives rise to weight morphologies independent the data. Specifically, in analogy condensed matter physics, derive a theory predict homogeneous state unstable way leads emergence periodic channel structures. We verified these structures by...
Abstract Objectives The drop in oestrogen levels during menopause coincides with the peak incidence of rheumatoid arthritis(RA) women, suggesting a role oestrogens its pathophysiology. However, timing effect RA-development is unknown. Studies final phase RA-development, from clinically suspect arthralgia(CSA) towards apparent arthritis, are lacking. We hypothesized that shorter lifetime exposure might be associated higher risk inflammatory arthritis(IA)-development women CSA and studied this...
The disease course and burden of rheumatoid arthritis(RA) may differ between females males, but existing data on these differences are limited often contradictory. Therefore, we investigated whether clinical outcomes patient-reported outcomes(PROs) female male RA patients over time. All female(n=286) male(n=139) patients, according to 1987 and/or 2010 criteria, from the tREACH trial, a stratified single-blinded trial with treat-to-target approach fixed medication protocol, were included....
Objective Rheumatoid arthritis (RA) and psoriatic (PsA) are currently treated similarly. However, it is unclear which patient-reported outcome (PRO) domains need specific attention in the management of RA PsA. Therefore, we aimed to determine difference disease impact between matched PsA patients at diagnosis after 1 year two different regions. Methods from treatment Rotterdam Early Arthritis CoHort trial (tREACH), Dutch southwest cohoRt (DEPAR) Leiden Clinic (EAC) were included. The was...
Patients with rheumatoid arthritis (RA) can be separated into two major subpopulations based on the absence or presence of serum anti-citrullinated protein antibodies (ACPAs). The more severe disease course in ACPA(+) RA and differences treatment outcome between these suggest that ACPA(-) are different subsets. identification T-helper (Th) cells specifically recognizing citrullinated peptides, combined strong association HLA-DRB1 ACPA positivity, point toward a pathogenic role Th RA. In this...
To identify and validate clinical baseline predictors associated with inadequate response (IR) to methotrexate (MTX) therapy in newly diagnosed patients rheumatoid arthritis (RA).In U-Act-Early, 108 disease-modifying antirheumatic drug (DMARD)-naive RA were randomised initiate MTX treated target until sustained remission (disease activity score assessing 28 joints (DAS28) <2.6 four or less swollen for ≥24 weeks) was achieved. If no remission, hydroxychloroquine added the treatment regimen...
Objectives To evaluate the 2-year clinical effectiveness of two gradual tapering strategies. The first strategy consisted conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (i.e., methotrexate in ~90%), followed by tumour necrosis factor inhibitor (TNF-inhibitor), second TNF-inhibitor first, csDMARD. Methods This multicentre single-blinded randomised controlled trial included patients with rheumatoid arthritis (RA) well-controlled disease for ≥3 consecutive months,...
Abstract Background We present a study protocol for randomized, double-blind, placebo-controlled trial that investigates the hypothesis if intervention in symptomatic phase preceding clinical arthritis (clinically suspect arthralgia (CSA)) is effective preventing progression from subclinical inflammation to clinically apparent persistent arthritis. Currently, rheumatoid (RA) can be recognized and diagnosed when (joint swelling) has become detectable at physical examination. Importantly, this...
Objective To investigate whether baseline concentrations of one‐carbon metabolism biomarkers are associated with treatment nonresponse and adverse events in rheumatoid arthritis (RA) patients receiving methotrexate (MTX). Methods A prospective derivation cohort (n = 285) validation 102) RA MTX were studied. Concentrations plasma homocysteine, serum vitamin B 12 , folate, erythrocyte 6 folate determined at after 3 months treatment. Nonresponse was assessed using the Disease Activity Score 28...
Objectives With early and intensive treatment many patients with RA attain remission. Aims were to investigate (1) the frequency time sustained remission subsequent tapering in initially treated conventional synthetic disease modifying anti-rheumatic drug ((cs)DMARD) strategies (2) flare regained csDMARDs biological (b)DMARDs during 2 years of follow-up. Methods Two-year follow-up data from Rotterdam Early Arthritis Cohort (tREACH) cohort used. Patients randomised initial triple DMARD...
Autoantibody responses increase years before the onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA. Cytokine chemokine levels also IA onset. However, course in at-risk stage CSA progression disease or non-progression is unknown. To understanding processes mediating development, we studied cytokine, related receptors gene expression patients who ultimately did not develop
Abstract Objectives To investigate the association between depression and anxiety inability to achieve remission in RA PsA patients. In addition, depressive symptoms disease activity components was explored. Methods A total of 400 367 patients from tREACH DEPAR were included, respectively. Patients had a possible or disorder if they scored &gt;7 on Hospital Anxiety Depression Scale (HADS). Remission defined as DAS44 &lt;1.6 DAPSA ≤ 4 PsA. Mixed models used assess depression/anxiety,...
Objective To investigate whether methotrexate (MTX) use, as compared to other therapies, and erythrocyte polyglutamate (MTXGlu) concentrations are associated with changes in glycosylated hemoglobin (HbA 1c ) levels rheumatoid arthritis (RA) patients. Methods The derivation cohort consisted of patients selected from the Treatment Rotterdam Early Arthritis Cohort who fulfilled 2010 American College Rheumatology/European League Against Rheumatism classification criteria for RA. Patients were...